Free Trial

Glaukos (GKOS) Stock Price, News & Analysis

Glaukos logo
$94.21 +4.42 (+4.92%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$94.17 -0.04 (-0.04%)
As of 08/22/2025 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Glaukos Stock (NYSE:GKOS)

Key Stats

Today's Range
$89.48
$94.71
50-Day Range
$84.80
$106.65
52-Week Range
$77.10
$163.71
Volume
688,079 shs
Average Volume
1.21 million shs
Market Capitalization
$5.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$127.42
Consensus Rating
Moderate Buy

Company Overview

Glaukos Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

GKOS MarketRank™: 

Glaukos scored higher than 95% of companies evaluated by MarketBeat, and ranked 63rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Glaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 10 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Glaukos has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Glaukos' stock forecast and price target.
  • Earnings Growth

    Earnings for Glaukos are expected to grow in the coming year, from ($1.08) to ($0.15) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Glaukos is -57.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Glaukos is -57.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Glaukos has a P/B Ratio of 7.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Glaukos' valuation and earnings.
  • Percentage of Shares Shorted

    7.07% of the float of Glaukos has been sold short.
  • Short Interest Ratio / Days to Cover

    Glaukos has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Glaukos has recently decreased by 21.24%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Glaukos does not currently pay a dividend.

  • Dividend Growth

    Glaukos does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.07% of the float of Glaukos has been sold short.
  • Short Interest Ratio / Days to Cover

    Glaukos has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Glaukos has recently decreased by 21.24%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Glaukos has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Glaukos this week, compared to 7 articles on an average week.
  • Search Interest

    Only 1 people have searched for GKOS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Glaukos insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.80% of the stock of Glaukos is held by insiders.

  • Percentage Held by Institutions

    99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Glaukos' insider trading history.
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Stock News Headlines

Are Investors Undervaluing Glaukos Corporation (NYSE:GKOS) By 43%?
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
Piper Sandler Reaffirms Their Buy Rating on Glaukos (GKOS)
Glaukos (GKOS) Q2 Revenue Jumps 30%
See More Headlines

GKOS Stock Analysis - Frequently Asked Questions

Glaukos' stock was trading at $149.94 on January 1st, 2025. Since then, GKOS shares have decreased by 37.2% and is now trading at $94.2070.

Glaukos Corporation (NYSE:GKOS) released its earnings results on Wednesday, July, 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. The firm's revenue was up 29.7% on a year-over-year basis.
Read the conference call transcript
.

Glaukos (GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos' top institutional investors include State Street Corp (3.64%), Ameriprise Financial Inc. (3.49%), Primecap Management Co. CA (3.19%) and Geode Capital Management LLC (2.32%). Insiders that own company stock include Joseph E Gilliam, Tomas Navratil, Thomas William Burns, Alex R Thurman, Marc Stapley, Mark J Foley, Gilbert H Kliman and Aimee S Weisner.
View institutional ownership trends
.

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA) and Netflix (NFLX).

Company Calendar

Last Earnings
7/30/2025
Today
8/22/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NYSE:GKOS
CIK
1192448
Employees
780
Year Founded
1998

Price Target and Rating

High Price Target
$165.00
Low Price Target
$72.00
Potential Upside/Downside
+35.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$146.37 million
Net Margins
-21.43%
Pretax Margin
-21.28%
Return on Equity
-8.59%
Return on Assets
-6.61%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
5.51
Quick Ratio
4.69

Sales & Book Value

Annual Sales
$383.48 million
Price / Sales
14.09
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$13.34 per share
Price / Book
7.06

Miscellaneous

Outstanding Shares
57,350,000
Free Float
54,024,000
Market Cap
$5.40 billion
Optionable
Optionable
Beta
0.78

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NYSE:GKOS) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners